Scalper1 News
The Bausch & Lomb division of Valeant Pharmaceuticals International (VRX) announced positive late-stage trial results of a new glaucoma drug Thursday and projected it could sell more than $1 billion a year. Valeant popped over 6% in morning trading in the stock market today, though by early afternoon it was up just over 3%. Bausch & Lomb licensed the drug, Vesneo, from French biotech Nicox before it was acquired by Valeant last year. The two phase Scalper1 News
Scalper1 News